Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
Stefanovic M, Tutusaus A, Martinez-Nieto GA, Bárcena C, de Gregorio E, Moutinho C, Barbero-Camps E, Villanueva A, Colell A, Marí M, García-Ruiz C, Fernandez-Checa JC, Morales A.
Stefanovic M, et al. Among authors: tutusaus a.
Oncotarget. 2016 Feb 16;7(7):8253-67. doi: 10.18632/oncotarget.6982.
Oncotarget. 2016.
PMID: 26811497
Free PMC article.